ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

Herberman Leaving NCI To Head New Pittsburgh Institute

July 12, 1985

NCI Phase II Trial Tests Vaccine Plus Hormone Therapy For Recurrent Prostate Cancer

August 26, 2005

Volasertib Shows Response In 31 Percent of Acute Myeloid Leukemia Patients

December 28, 2012

NCI Leaders, Others Defend Cancer Program Against Bailar’s Charge They Are Losing War Against Cancer

May 16, 1986

Believers “Flout Fundamental Law Of Physics,” Park Says.

August 1, 2008

Editorial: Rumor Mill Fills The Gap When Access Denied

December 16, 1994